CYTH vs. INAB, DYAI, OKYO, QNCX, SABS, ESLA, ACHL, TARA, INKT, and SRZN
Should you be buying Cyclo Therapeutics stock or one of its competitors? The main competitors of Cyclo Therapeutics include IN8bio (INAB), Dyadic International (DYAI), OKYO Pharma (OKYO), Quince Therapeutics (QNCX), SAB Biotherapeutics (SABS), Estrella Immunopharma (ESLA), Achilles Therapeutics (ACHL), Protara Therapeutics (TARA), MiNK Therapeutics (INKT), and Surrozen (SRZN). These companies are all part of the "biological products, except diagnostic" industry.
IN8bio (NASDAQ:INAB) and Cyclo Therapeutics (NASDAQ:CYTH) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, community ranking, dividends, analyst recommendations, earnings, profitability and institutional ownership.
IN8bio presently has a consensus price target of $10.00, indicating a potential upside of 870.87%. Cyclo Therapeutics has a consensus price target of $3.20, indicating a potential upside of 128.57%. Given Cyclo Therapeutics' higher possible upside, analysts plainly believe IN8bio is more favorable than Cyclo Therapeutics.
In the previous week, IN8bio had 5 more articles in the media than Cyclo Therapeutics. MarketBeat recorded 8 mentions for IN8bio and 3 mentions for Cyclo Therapeutics. IN8bio's average media sentiment score of 1.18 beat Cyclo Therapeutics' score of 0.26 indicating that Cyclo Therapeutics is being referred to more favorably in the news media.
92.1% of IN8bio shares are owned by institutional investors. Comparatively, 68.6% of Cyclo Therapeutics shares are owned by institutional investors. 33.0% of IN8bio shares are owned by company insiders. Comparatively, 29.8% of Cyclo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Cyclo Therapeutics has higher revenue and earnings than IN8bio. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than IN8bio, indicating that it is currently the more affordable of the two stocks.
IN8bio has a beta of 0.05, meaning that its stock price is 95% less volatile than the S&P 500. Comparatively, Cyclo Therapeutics has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500.
IN8bio received 13 more outperform votes than Cyclo Therapeutics when rated by MarketBeat users. However, 77.78% of users gave Cyclo Therapeutics an outperform vote while only 68.97% of users gave IN8bio an outperform vote.
IN8bio has a net margin of 0.00% compared to IN8bio's net margin of -1,720.76%. Cyclo Therapeutics' return on equity of -151.40% beat IN8bio's return on equity.
Summary
IN8bio beats Cyclo Therapeutics on 11 of the 16 factors compared between the two stocks.
Get Cyclo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CYTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CYTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cyclo Therapeutics Competitors List
Related Companies and Tools
